Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass: The role of tissue injury by surgical incision

Chest

Volumn 116, Issue 4, 1999, Pages 892-898

  Gu, Y John ^b   Mariani, Massimo A ^b   Boonstra, Piet W ^b   Grandjean, Jan G ^b   Van Oeveren, Willem ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

Cardiopulmonary bypass; Complement; Coronary disease; Inflammation; Interleukin 6; Minimally invasive; Tissue injury

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT MEMBRANE ATTACK COMPLEX; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; FEMALE; HUMAN; IMMUNOREGULATION; MALE; PRIORITY JOURNAL; STERNOTOMY; SURGICAL WOUND; THORACOTOMY;

EID: 0003084322     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.116.4.892     Document Type: Article

References (31)

1. 1 Chenoweth DE, Cooper SW, Hugli TE, et al. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981; 304:497-503
2. 2 Kirklin JK, Westaby S, Blackstone EH, et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86:845-857
3. 3 van Oeveren W, Kazatchkine MD, Descamps-Latscha B, et al. Deleterious effects of cardiopulmonary bypass: a prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 1985; 89:888-899
4. 4 Videm V, Fosse E, Mollnes TE, et al. Complement activation by extracorporeal circulation: effects of precoating a membrane oxygenator circuit with human whole blood. Scand J Thorac Cardiovasc Surg 1988; 22:251-256
5. 5 Glovsky MM, Hugli TE, Ishizaka T, et al. Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release. J Clin Invest 1979; 64:804-811
6. 6 Takabayashi T, Vannier E, Clark BD, et al. A new biological role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. J Immunol 1996; 156:3455-3460
7. 7 Webster RO, Hong SR, Johnston RB Jr, et al. Biological effects of human complement fragments C5a and C5a desArg on neutrophil function. Immunopharmacology 1980; 2:201-219
8. 8 Crawford MH, Grover FL, Kolb WP, et al. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 1988; 78:1449-1458
9. 9 Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55:552-559
10. 10 Hahn-Pedersen J, Sorensen H, Kehlet H. Complement activation during surgical procedures. Surg Gynecol Obstet 1978; 146:66-68
11. 11 Heideman M. Complement activation in tro induced by endotoxin and injured tissue. J Surg Res 1979; 26:670-673
12. 12 Fosse E, Mollnes TE, Ingvaldsen B. Complement activation during major operations with or without cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987; 93:860-866
13. 13 Benetti FJ, Naselli G, Wood M, et al. Direct myocardial revascularization without extracorporeal circulation: experience in 700 patients. Chest 1991; 100:312-316
14. 14 Boonstra PW, Grandjean JG, Mariani MA. Improved method for direct coronary grafting without CPB via anterolateral small thoracotomy. Ann Thorac Surg 1997; 63:567-569
15. 15 Mariani MA, Boonstra PW, Grandjean JG, et al. Minimally invasive coronary artery bypass grafting versus coronary angioplasty for isolated type C stenosis of the left anterior descending artery. J Thorac Cardiovasc Surg 1997; 114:434-439
16. 16 Gu YJ. Mariani M, van Oeveren W, et al. Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting. Ann Thorac Surg 1998; 65:420-424
17. 17 Gong J, Larsson R, Nilsson Ekdahl K, et al. Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immnnol 1996; 16:222-229
18. 18 Kirklin JK, Chenoweth DE, Naftel DC, et al. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. Ann Thorac Surg 1986; 41:193-199
19. 19 Volanakis JE. Transcriptional regulation of complement genes. Annu Rev Immunol 1995; 13:277-305
20. 20 Fransen E, Maessen J, Dentener M, et al. Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. Chest 1998; 113:1290-1295
21. 21 Edgington TS, Mackman N, Brand K, et al. The structural biology of expression and function of tissue factor. Thromb Hemost 1991; 66:67-79
22. 22 Berge V, Johnson E, Berge KE. Interleukin-1 alpha, interleukin-6 and tumor necrosis factor alpha increase the synthesis and expression of the functional alternative and terminal complement pathways by human umbilical vein endothelial cells in vitro. APMIS 1996; 104:213-219
23. 23 Bennett WR, Yawn DH, Migliore PJ, et al. Activation of the complement system by recombinant tissue plasminogen activator. J Am Coll Cardiol 1987; 10:627-632
24. 24 Schaiff WT, Eisenberg PR. Direct induction of complement activation by pharmacologic activation of plasminogen. Coron Artery Dis 1997; 8:9-18
25. 25 Tabuchi N, de Haan J, Boonstra PW, et al. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass J Thorac Cardiovasc Surg 1993; 106:828-833
26. 26 de Haan J, Boonstra PW, Tabuchi N, et al. Retransfusion of thoracic wound blood during heart surgery obscures biocompatibility of the extracorporeal circuit. J Thorac Cardiovasc Surg 1996; 111:272-275
27. 27 Gu YJ, de Haan J, Brenken UPM, et al. Clotting and fibrinolytic disturbance during lung transplantation: effect of low-dose aprotinin. J Thorac Cardiovasc Surg 1996; 112:599-606
28. 28 Salama A, Hugo F, Heinrich D, et al. Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N Engl J Med 1988; 318: 408-414
29. 29 Arom KV, Emery RW, Nicoloff DM, et al. Minimally invasive direct coronary artery bypass grafting: experimental and clinical experiences. Ann Thorac Surg 1997; 63:S48-S52
30. 30 Krause TJ. Minimally invasive coronary artery bypass grafting: what is the best approach [letter]? Ann Thorac Surg 1998; 65:1195
31. 31 Mariani MA, Boonstra PW, Grandjean JC. Minimally invasive coronary surgery: fad or future? This promising technique needs testing in randomised trials [editorial]. BMJ 1998; 316:88